Low dose Naltrexone for induction of remission in inflammatory bowel disease patients

BACKGROUND: Around 30% of patients with inflammatory bowel disease (IBD) are refractory to current IBD drugs or relapse over time. Novel treatments are called for, and low dose Naltrexone (LDN) may provide a safe, easily accessible alternative treatment option for these patients. We investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lie, Mitchell R. K. L., van der Giessen, Janine, Fuhler, Gwenny M., de Lima, Alison, Peppelenbosch, Maikel P., van der Ent, Cokkie, van der Woude, C. Janneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845217/
https://www.ncbi.nlm.nih.gov/pubmed/29523156
http://dx.doi.org/10.1186/s12967-018-1427-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845217/
https://www.ncbi.nlm.nih.gov/pubmed/29523156
http://dx.doi.org/10.1186/s12967-018-1427-5

Ejemplares similares